The progress in understanding the pathophysiology of hidradenitis suppurativa appears to be leading to treatment strategies ...
Eilean Therapeutics announced the advancement of ZE74-0282 into first-in-human clinical development. ZE74-0282 is a novel, highly selective inhibitor of the mutated Janus kinase 2 (JAK2) V617F variant ...
iOnctura, a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, announces it has dosed the first patient in its phase I/II clinical trial evaluating roginolisib in ...
First patient dosed in Phase I/II HEMA-MED clinical trial (NCT06887803) evaluating the tolerability and efficacy profile of roginolisib (PI3Kδ inhibitor) plus ruxolitinib in myelofibrosis (MF) ...
Nuvisertib and momelotinib combination therapy improved symptom burden, spleen volume, and anemia outcomes in relapsed/refractory myelofibrosis patients. The combination targets PIM1 and JAK pathways, ...
Inflammatory molecules circulating in the blood may worsen disease symptoms and points to new opportunities for targeted therapy.
A new study published in the journal of Inflammopharmacology showed that in individuals with moderate-to-severe atopic ...
Patients with chronic spontaneous urticaria experienced relief in itch and hives by day 3 with povorcitinib, according to data presented at the American College of Allergy, Asthma & Immunology Annual ...
Researchers have found in a 52-week real-world cohort that baricitinib showed sustained effectiveness and good tolerability ...
It can be a real pain in the neck. Rheumatoid arthritis, or RA, is an autoimmune disease in which the body mistakenly attacks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback